|
Feb 28
|
Praxis hits trial setback; Bristol Myers lays off staff in New Jersey
|
|
Feb 28
|
Bristol-Myers Squibb (BMY): Buy, Sell, or Hold Post Q4 Earnings?
|
|
Feb 26
|
Bristol-Myers Squibb Company (BMY): Top Stock to Buy from Dividend Stock Portfolio For Income
|
|
Feb 26
|
Got $200? 2 Healthcare Stocks to Buy and Hold Forever
|
|
Feb 25
|
Why Bristol-Myers Squibb Co (BMY) Went Up On Monday?
|
|
Feb 25
|
FDA accepts BMS’ Opdivo-Yervoy combo sBLA for colorectal cancer
|
|
Feb 24
|
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application for Opdivo® Plus Yervoy® for Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient...
|
|
Feb 21
|
Prothena Q4 Earnings Miss Estimates, Pipeline Progress in Focus
|
|
Feb 20
|
BMS’ Opdivo plus chemotherapy shows OS benefit in Phase III NSCLC study
|
|
Feb 19
|
Bristol Myers Cancer Drug Opdivo In Combination With Chemo Shows Improved Overall Survival In Certain Patients With Lung Cancer
|
|
Feb 19
|
Bristol Myers Squibb Announces Opdivo® Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant and Clinically Meaningful Overall Survival in Resectable Non-Small Cell Lung Cancer
|
|
Feb 18
|
Bristol Myers announces new five-year results from POETYK PSO trial
|
|
Feb 17
|
Bristol Myers Squibb’s Sotyktu shows consistent safety profile in psoriasis trial
|
|
Feb 17
|
Why Bristol-Myers Squibb (BMY) Is Among the Best Drug Stocks to Buy Now
|
|
Feb 16
|
New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis
|
|
Feb 14
|
BioArctic AB (BRCTF) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Profitability ...
|
|
Feb 13
|
Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial
|
|
Feb 12
|
Bristol-Myers Squibb Company (BMY) – Jim Cramer: “No, No, You Don’t Hold”
|
|
Feb 12
|
Shareholders in Bristol-Myers Squibb (NYSE:BMY) have lost 7.2%, as stock drops 5.4% this past week
|
|
Feb 11
|
BMY Down 7% Post Q4 Earnings: Should You Buy, Sell or Hold the Stock?
|